Introduction

Metastases to the bone occur in up to 75% of patients with breast and prostate cancer and can severely affect quality of life. This Brief examines trends in the bone metastases market for both prostate and breast cancer, the potential of the drugs for cancer-related osteoporosis and what pharmaceutical companies need to do to consolidate their positions in the market. 

Scope

Overview of treatment of bone metastases in breast and prostate cancer 

Potential of bisphosphonates in the osteoporosis market

Clinical application of bisphosphonates in adjuvant setting 

Opinions from leading physicians in the field of bisphosphonates 

Report Highlights

Novartis’ Zometa will overtake Aredia as the gold standard treatment for bone metastases imminently 

The use of Zometa in combination with anti-aromatase agents will be the key to Novartis’ expansion in the bone metastases market 

There is significant potential of bisphosphonates in the treatment of hormonal therapy-induced osteoporosis, especially in the prostate cancer market 

Reasons to Purchase

Predict the commercial potential of bisphosphonates for osteoporosis to determine the viability of entry into the market 

Determine the possible clinical applications of bisphosphonates and maximize the full market potential of your product  

Enhance your commercial positioning by understanding the cost-effectiveness of bisphosphonate therapy for bone metastases 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a298